


7-Oxostaurosporine

Cat. No.:	HY-120515
CAS No.:	125035-83-8
Molecular Formula:	C ₂₈ H ₂₄ N ₄ O ₄
Molecular Weight:	480.51
Target:	PKC
Pathway:	Epigenetics; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	7-Oxostaurosporine is a potent protein kinase C (PKC) inhibitor that effectively inhibits tumor growth by inducing apoptosis and inhibiting the nuclear factor (NF)-κB/p-p65 pathway ^{[1][2]} .
In Vitro	7-Oxostaurosporine (50 nM, 24 h) can lead to an increase in plasma membrane sphingomyelin in CHO cells but does not alter ceramide content ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	7-Oxostaurosporine (6 mg/kg, once daily, intravenous) significantly reduces tumour growth with a tumour growth inhibition (TGI) of 56.1% and no significant effect on body weigh ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Masashi Maekawa, et al. Staurosporines decrease ORMDL proteins and enhance sphingomyelin synthesis resulting in depletion of plasmalemmal phosphatidylserine. *Sci Rep.* 2016 Nov 2;6:35762.

[2]. Feng Song, et al. The anticancer activity of carbazole alkaloids. *Arch Pharm (Weinheim).* 2022 Jan;355(1):e2100277.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA